• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Announces Board Expansion and Changes

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MDRX alert in real time by email

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors

    Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives.

    As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silverman, effective February 20, 2025. The Company will also identify two additional independent directors to join the Board, subject to Kent Lake's approval; one will be appointed by March 22, 2025, and the other will be appointed promptly following the filing of the Company's annual report on Form 10-K for the fiscal year ended December 31, 2022 (the "2022 Form 10-K").

    On February 14, 2025, Jonathan Judge stepped down from the Board, effective immediately, and Chairman Greg Garrison will retire from the Board shortly following the filing of the 2022 Form 10-K.

    Vinit Asar is the former Chief Executive Officer ("CEO") of Hanger, Inc. ("Hanger") and brings 30 years of diversified global healthcare leadership experience in medical services and non-acute healthcare services. While CEO of Hanger, he grew revenue from $700 million to $1.4 billion via organic and inorganic growth combined with strategic divestitures and business exits. He also significantly strengthened Hanger's infrastructure, leadership team and governance while navigating a financial restatement and NYSE delisting process. He currently serves as the Executive Chairman of Hanger, which was taken private in 2022, and on the board of directors of ZimVie Inc. (NASDAQ:ZIMV).

    Louis Silverman is a seasoned healthcare executive currently serving as Chairman and CEO of Hicuity Health, the nation's largest provider of 24x7 high acuity telemedicine services. He brings over 30 years of leadership experience in health information technology and technology-enabled healthcare services. Mr. Silverman previously served as the CEO of Quality Systems (NASDAQ:QSII), a leader in the ambulatory electronic healthcare record market. Silverman also served as CEO of Marina Medical, a specialty revenue cycle management company. He currently serves on the board of directors of Oncocyte Corporation (NASDAQ:OCX).

    "We appreciate our stockholders' efforts to put forth well-qualified individuals to serve on the Board," stated Greg Garrison, Chairman of the Board. "In parallel with ongoing refreshment planning, we are adding new independent directors with deep strategic planning, finance, healthcare and restatement experience to strengthen the Board as we focus on our priorities: executing our standalone strategy, becoming current in financial reporting and relisting our common stock."

    Mr. Garrison continued, "Jon has been an invaluable member of our Board for almost nine years, bringing exceptional leadership, insight, and dedication throughout his tenure. On behalf of the Board and the entire organization, I sincerely thank him for his perspective, partnership, and commitment to Veradigm. We wish him success in his future endeavors."

    "On behalf of the entire Veradigm team, I want to express our sincere gratitude to Greg, who has served as an important thought partner to management for nearly a decade. We are incredibly thankful for his guidance and leadership throughout his tenure, particularly in connection with the ongoing restatement," said Tom Langan, Interim Chief Executive Officer of Veradigm.

    Benjamin Natter, Managing Member of Kent Lake Capital, added, "We appreciate the constructive dialogue with the Board and management team and are pleased to have reached this agreement. As long-term investors, we believe that Veradigm is well positioned to deliver value to customers and the healthcare system while also generating attractive returns for shareholders. We believe these new directors will provide the right experience and perspective during this critical time."

    Kent Lake has agreed to abide by certain customary standstill commitments in connection with the Cooperation Agreement. The full Agreement will be filed by the Company with the U.S. Securities and Exchange Commission as an exhibit to a Current Report on Form 8-K.

    About Veradigm®

    Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

    © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250220886186/en/

    Investors:

    Jenny Gelinas

    312-506-1237

    jenny.gelinas@veradigm.com

    Media:

    Concetta Rasiarmos

    630-740-3152

    concetta.rasiarmos@veradigm.com

    Get the next $MDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDRX
    $OCX
    $ZIMV

    CompanyDatePrice TargetRatingAnalyst
    ZimVie Inc.
    $ZIMV
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    ZimVie Inc.
    $ZIMV
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    ZimVie Inc.
    $ZIMV
    4/10/2025$16.00Buy
    B. Riley Securities
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    ZimVie Inc.
    $ZIMV
    3/13/2025Buy → Hold
    Needham
    ZimVie Inc.
    $ZIMV
    5/16/2024$20.00Hold → Buy
    Needham
    Veradigm Inc.
    $MDRX
    3/19/2024$15.00 → $10.00Buy → Hold
    Deutsche Bank
    Veradigm Inc.
    $MDRX
    1/3/2024$11.00Equal Weight
    Barclays
    More analyst ratings

    $MDRX
    $OCX
    $ZIMV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

    4 - Oncocyte Corp (0001642380) (Issuer)

    2/11/25 7:00:32 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

    4 - Oncocyte Corp (0001642380) (Issuer)

    2/11/25 5:00:15 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

    4 - Oncocyte Corp (0001642380) (Issuer)

    2/10/25 8:43:04 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $MDRX
    $OCX
    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Veradigm to Release Business Update May 26th and Host Investor Call May 27th

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on Tuesday, May 26, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update on Wednesday, May 27th, at 8:00 a.m. Eastern Time. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, May 26, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call on Wednesday, May 27, 2026 at 8:00 a.m. East

    5/26/26 8:01:00 AM ET
    $MDRX
    EDP Services
    Technology

    InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

    SOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases. "We are excited to welcome Alec and Mitch to InterVenn's Board of Directors at a pivotal moment fo

    5/18/26 9:02:00 AM ET
    $IPA
    $OCX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Veradigm Launches Health Network Architecture to Level the Playing Field for Independent Practices

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced the availability of the Veradigm Health Network Architecture™ to early adopter customers. Veradigm Health Network Architecture provides independent practices a single real-time view of their clinical, financial, and operational performance and helps close a capability gap that has historically separated independent practices from large health systems. It connects data across the products practices already use, from EHR and practice management to clearinghouse and patient portal. Instead of overnight batch cycles and manual data stitching, information flows together as

    5/6/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    $OCX
    $ZIMV
    SEC Filings

    View All

    Veradigm Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Veradigm Inc. (0001124804) (Filer)

    2/17/26 4:10:26 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Veradigm Inc.

    SCHEDULE 13G/A - Veradigm Inc. (0001124804) (Subject)

    2/13/26 1:08:01 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form 8-A12G/A filed by Veradigm Inc.

    8-A12G/A - Veradigm Inc. (0001124804) (Filer)

    2/2/26 4:47:45 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    $OCX
    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Kanaglekar Indraneel returned 63,438 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:45:41 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Director Crawford Sally returned 40,127 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:35:06 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Officer Schneider Sandra returned 40,794 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    10/20/25 5:24:52 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $MDRX
    $OCX
    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on ZimVie with a new price target

    B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

    4/10/25 12:44:28 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $MDRX
    $OCX
    $ZIMV
    Leadership Updates

    Live Leadership Updates

    View All

    InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

    SOUTH SAN FRANCISCO, Calif., May 18, 2026 /PRNewswire/ -- InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company's Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases. "We are excited to welcome Alec and Mitch to InterVenn's Board of Directors at a pivotal moment fo

    5/18/26 9:02:00 AM ET
    $IPA
    $OCX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Veradigm Doubles India-Based Employee Footprint, Adds New Managing Director

    Veradigm® India Private Limited, the India subsidiary of Veradigm (OTC:MDRX), a US-based leader in clinical and revenue cycle solutions for independent practices, today announced a major expansion of its Pune operations, doubling its office capacity and adding a new managing director. This milestone marks a significant chapter in Veradigm's growth journey, reflecting the company's continued investment in its people, its infrastructure, and its long-term vision for India. Located in one of Pune's prime business districts, the expansion is designed to support scale, inspire collaboration, and create an environment where teams can do their best work. It is a direct expression of Veradigm's f

    4/27/26 10:31:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Appoints Christian Greyenbuhl as Chief Financial Officer

    Veradigm Inc. (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced the appointment of Christian Greyenbuhl as Chief Financial Officer of the Company, effective on the later of May 11, 2026 and the first business day after Veradigm files its Annual Report on Form 10-K for its 2023 and 2024 fiscal years, or as otherwise agreed. Mr. Greyenbuhl is a seasoned operator and finance executive with more than 25 years of experience across both global public and private companies. He brings a strong track record as a general manager and operator, having served as general manager of businesses of Automatic Data Processing, Inc. ("ADP") on two occ

    4/6/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    $OCX
    $ZIMV
    Financials

    Live finance-specific insights

    View All

    Veradigm to Release Business Update May 26th and Host Investor Call May 27th

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on Tuesday, May 26, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update on Wednesday, May 27th, at 8:00 a.m. Eastern Time. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, May 26, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call on Wednesday, May 27, 2026 at 8:00 a.m. East

    5/26/26 8:01:00 AM ET
    $MDRX
    EDP Services
    Technology

    Veradigm to Release Business Update February 17th and Host Investor Call February 18th

    Veradigm® (OTC:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February 18, 2026. Update Call Details Veradigm plans to issue a press release after the close of regular stock market hours on Tuesday, February 17, 2026. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm invest

    2/10/26 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Veradigm Amends and Extends Stockholder Rights Plan

    Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene

    8/20/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    $MDRX
    $OCX
    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

    SC 13G/A - Oncocyte Corp (0001642380) (Subject)

    12/9/24 5:30:06 PM ET
    $OCX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology